• Something wrong with this record ?

Effective use of fondaparinux in patient with unresponsiveness to nadroparin

JM. Hartinger, A. Svobodová, I. Malíková, R. Šachl, O. Slanař

. 2021 ; 46 (2) : 539-542. [pub] 20201205

Language English Country Great Britain

Document type Case Reports

Persistent link   https://www.medvik.cz/link/bmc22004490

Grant support
Q25 Univerzita Karlova v Praze

WHAT IS KNOWN AND OBJECTIVE: Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. CASE SUMMARY: We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti-Xa measurements. The antithrombin levels were within the normal range. WHAT IS NEW AND CONCLUSION: To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004490
003      
CZ-PrNML
005      
20240522102107.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jcpt.13328 $2 doi
035    __
$a (PubMed)33277918
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hartinger, Jan $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0224709
245    10
$a Effective use of fondaparinux in patient with unresponsiveness to nadroparin / $c JM. Hartinger, A. Svobodová, I. Malíková, R. Šachl, O. Slanař
520    9_
$a WHAT IS KNOWN AND OBJECTIVE: Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. CASE SUMMARY: We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti-Xa measurements. The antithrombin levels were within the normal range. WHAT IS NEW AND CONCLUSION: To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
650    _2
$a senioři $7 D000368
650    _2
$a antikoagulancia $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000925
650    _2
$a hemokoagulace $x účinky léků $7 D001777
650    _2
$a fondaparinux $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000077425
650    _2
$a heparin nízkomolekulární $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D006495
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nadroparin $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D017762
655    _2
$a kazuistiky $7 D002363
700    1_
$a Svobodová, Alžběta $u II. Surgical Clinic - Cardiovascular Surgery, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Malíková, Ivana $u Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Šachl, Robert $u Department of Anesthesiology and Intensive Care, Institute of Pharmacology, 1st Faculty of Medicine and Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Slanař, Ondřej $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00007277 $t Journal of clinical pharmacy and therapeutics $x 1365-2710 $g Roč. 46, č. 2 (2021), s. 539-542
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33277918 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240522102103 $b ABA008
999    __
$a ok $b bmc $g 1751835 $s 1155639
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 46 $c 2 $d 539-542 $e 20201205 $i 1365-2710 $m Journal of clinical pharmacy and therapeutics $n J Clin Pharm Ther $x MED00007277
GRA    __
$a Q25 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options